Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 12/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984847 | 1.00 | PBRM1 (0.67) | PBRM1MAOBACHETDP1CYP19A1 | |
| SCHEMBL9819050 | 0.87 | MAOB (0.63) | PBRM1MAOB | |
| SCHEMBL3681000 | 0.81 | PBRM1 (0.69) | PBRM1MAOBACHETDP1CYP19A1 | |
| SCHEMBL3683723 | 0.81 | PBRM1 (0.69) | PBRM1MAOBACHETDP1CYP19A1 | |
| SCHEMBL31015961 | 0.80 | PBRM1 (1.00) | PBRM1MAOBTDP1CYP19A1KDM4E | |
| SCHEMBL18013010 | 0.80 | PBRM1 (1.00) | PBRM1MAOBTDP1CYP19A1KDM4E | |
| SCHEMBL13335352 | 0.80 | PBRM1 (0.43) | PBRM1MAOBACHETDP1BRD4 | |
| SCHEMBL10076980 | 0.80 | PBRM1 (0.67) | PBRM1MAOBTDP1CYP19A1KDM4E | |
| SCHEMBL68075 | 0.80 | PBRM1 (0.67) | PBRM1MAOBTDP1CYP19A1KDM4E | |
| SCHEMBL23788312 | 0.80 | SIRT2 (0.46) | PBRM1MAOBCYP19A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158667-B2 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2012-04-17 | — | — | US | disclosed |
| US-8158667-B2 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2012-04-17 | — | — | US | disclosed |
| US-8158667-B2 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2012-04-17 | — | — | US | disclosed |
| WO-2010065024-A1 | TOPICAL TREATMENT OF CATARACTS IN DOGS | KADOR PETER F (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065024-A1 | TOPICAL TREATMENT OF CATARACTS IN DOGS | KADOR PETER F (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | disclosed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | disclosed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | disclosed |
| EP-0230379-B1 | CHROMAN- AND THIOCHROMAN-4-ACETIC ACIDS USEFUL IN THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4853410-A | Hydroxyacetic acid derivatives for the treatment of diabetic complications | PFIZER INC. (US) | 1989-08-01 | — | — | US | disclosed |
| WO-1987004344-A1 | HYDROXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1987-07-30 | — | — | WO | disclosed |
| EP-0230379-A2 | Chroman- and thiochroman-4-acetic acids useful in the treatment of diabetic complications | PFIZER INC. (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082415-A1 | Topical treatment of cataracts in dogs | AKR1A1, AKR1B1, AKR1C1 | PBRM1 1126/4885MAOB 3288/4885ACHE 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.